| Today's Edition
Wednesday June 15th, 2016
Stay ahead of the pack with "The QualityStocks Daily", our summary formatted newsletter
containing stock tips from hundreds of online investment newsletters.
Daily.QualityStocks.net
Ekso Bionics Holdings, Inc. (EKSO)
Total Wealth, Daily Trade Alert, Money Morning, Uncommon Wisdom, Promotion Stock Secrets, PennyStockProphet, Penny Pick Finders, Planet Penny Stocks, Buzz Stocks, Stock Onion, and Total Wealthreported on Ekso Bionics Holdings, Inc. (EKSO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Ekso Bionics Holdings, Inc. designs, develops, and commercializes exoskeletons, or wearable robots. Exoskeletons are ready-to-wear, battery-powered robots. They are strapped over the user's clothing, enabling individuals to achieve mobility, strength, or endurance not otherwise possible. The Company’s lead product is Ekso™. Ekso™ has helped thousands of people living with paralysis take millions of steps not otherwise possible. Ekso Bionics Holdings is based in Richmond, California.
Its Ekso™ is a robotic exoskeleton used for the rehabilitation of individuals with lower extremity weakness, paralysis or hemiparesis (weakness on one side of the body) owing to such neurological conditions as stroke, spinal cord injury or disease, and traumatic brain injury. Ekso™ is a wearable bionic suit. It enables individuals with any amount of lower extremity weakness to stand up and walk over ground with a natural, full weight bearing, and reciprocal gait. Walking is achieved through the user’s weight shifts to activate sensors in the device, which initiate steps. Battery-powered motors drive the legs, replacing deficient neuromuscular function.
Ekso GT™ with SmartAssist™ features include the next generation of adaptive assistance software, permitting a greater number of interactive steps; PreGait, a group of early mobilization activities for pre-ambulatory patients preparing for gait therapy; and FreeGait, an advanced mode for patients progressing to community ambulation.
Ekso Bionics Holdings has acquired the gravity balancing arm technologies of Equipois, LLC. This includes the zeroG™ and X-Ar™ products. The intent of this acquisition is to expand its exoskeleton capabilities in the industrial market. The patented technology behind the Equipois products enables workers to maneuver tools and other objects as if weightless.
This past April, Ekso Bionics Holdings announced that it received clearance from the U.S. Food and Drug Administration (FDA) to market its Ekso GT robotic exoskeleton for use in the treatment of individuals with hemiplegia because of stroke, individuals with spinal cord injuries at levels T4 to L5, and individuals with spinal cord injuries at levels of T3 to C7 (ASIA D), in accordance with device’s labeling. The Ekso GT is the first exoskeleton cleared by the FDA for use with stroke patients.
Ekso Bionics Holdings, Inc. (EKSO), closed Wednesday's trading session at $5.20, down 0.48%, on 20,323 volume with 133 trades. The average volume for the last 60 days is 6,940 and the stock's 52-week low/high is $4.55/$11.06.
|
